

Customer:
Pure Health Peptides

EA Sample ID: 26EA0126-032
Sample Name: (5) NAD+
Sample Type: Powder
Batch/Lot: CHA-011926

Date Received:
01/27/2026
Date Completed:
02/02/2026



ETHOS
ANALYTICS

CERTIFICATE OF ANALYSIS

Summary of Results

<u>Analysis Type</u>	<u>Method</u>	<u>Date Tested</u>	<u>Status</u>	
NAD+	HPLC	02/02/2026	Complete	

Serving Size: N/A

Label Claim Profile

<u>Analyte</u>	<u>Result</u>	<u>Specification</u>	<u>LOQ (%)</u>
NAD+	110.63mg/vial	Report mg/vial	0.1
Identity of the analyte was confirmed by retention time concordance with a certified reference standard, per USP <621>			
Chromatographic Purity	>99%	>99%	0.1

NOTES: Injectable peptides may include acceptable salts, sugars, or buffering agents added to improve solubility and stability. These excipients are non-chromophoric, typically not detected by HPLC, and are not considered impurities.

LOD = LIMIT OF DETECTION; LOQ = LIMIT OF QUANTIFICATION



Ethos Analytics Laboratory
3020 E Camelback Rd STE 397
Phoenix, AZ 85016
Info@Ethosanalytics.io
www.Ethosanalytics.io
Lic #: 000026LRCND60176649
ISO/IEC 17025 Acc #: 117798

Noel Samsum
Laboratory Director
2-Feb-2026

The sample analyzed was inspected and is free from visual mold, mildew, and foreign matter. The testing procedures, equipment calibration, and maintenance are all in accordance with ISO/IEC 17025:2017 standards. The presented report is only applicable to the sample specified above and may not be applied to any similar or identical products. Reports are prohibited from being reproduced with alterations of any kind.